Physician profile
Patrick Osam
NPI 1720030596
$4,308.02
in general payments reported to CMS, 2019-2025
12 companies · $758 in 2025
The $758 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $262 · 2022: $1,716 · 2023: $541 · 2024: $1,031 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,330.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,448.73 | 2022-2023 | Vistaseal |
| Ethicon US, LLC | $866.52 | 2021-2025 | Echelon; Endopath, Surgicel Nu-Knit, Vistaseal |
| Endogastric Solutions, INC | $561.24 | 2024 | Esophyx |
| Boston Scientific Corporation | $522.42 | 2023-2025 | General - Therapies, Advantage System |
| Johnson & Johnson Health Care Systems INC. | $273.76 | 2022 | |
| Abbott Laboratories | $164.89 | 2025 | Xience Skypoint |
| W. L. Gore & Associates, INC. | $156.67 | 2025 | Gore Synecor Preperitoneal Biomaterial |
| Intuitive Surgical, INC. | $134.45 | 2024 | |
| Baxter Healthcare | $93.32 | 2025 | Starling System |
| Davol INC. | $37.71 | 2022 | |
| Abbvie INC. | $32.47 | 2021-2025 | |
| Mentor Worldwide LLC | $15.84 | 2023 | Artoura Breast Tissue Expander |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Osam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.